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Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by a 
wide spectrum of deficits in social interaction, communication, and behavior. There is a 
significant genetic component to ASD, yet no single gene variant accounts for >1% of 
incidence. Posttranscriptional mechanisms such as microRNAs (miRNAs) regulate gene 
expression without altering the genetic code. They are abundant in the developing brain 
and are dysregulated in children with ASD. Patterns of miRNA expression are altered in the 
brain, blood, saliva, and olfactory precursor cells of ASD subjects. The ability of miRNAs to 
regulate broad molecular pathways in response to environmental stimuli makes them an 
intriguing player in ASD, a disorder characterized by genetic predisposition with ill-defined 
environmental triggers. In addition, the availability and extracellular stability of miRNAs make 
them an ideal candidate for biomarker discovery. Here, we discuss 27 miRNAs with overlap 
across ASD studies, including 3 miRNAs identified in 3 or more studies (miR-23a, miR-146a, 
and miR-106b). Together, these 27 miRNAs have 1245 high-confidence mRNA targets, a 
significant number of which are expressed in the brain. Furthermore, these mRNA targets 
demonstrate over-representation of autism-related genes with enrichment of neurotrophic 
signaling molecules. Brain-derived neurotrophic factor, a molecule involved in hippocampal 
neurogenesis and altered in ASD, is targeted by 6 of the 27 miRNAs of interest. This neu-
rotrophic pathway represents one intriguing mechanism by which perturbations in miRNA 
signaling might influence central nervous system development in children with ASD.
Keywords: autism, microrNA, neurodevelopment, biomarker
BAcKGrOUND
In 1993, the first non-coding antisense RNA sequence was described in Caenorhabditis elegans 
(1, 2) and termed microRNA (miRNA). Over the next 10 years, the roles of miRNAs in modifying 
mRNA translation and their potential involvement in human diseases were revealed (3, 4). We 
now know that miRNAs play an important role in central nervous system (CNS) development 
and function  (5,  6) and that dysregulation of miRNAs is tied to alterations in behavior and 
Abbreviations: ADI-R, autism diagnostic interview – revised; ADOS, Autism Diagnostic Observation Schedule; ASD, autism 
spectrum disorder; AUC, area under the curve; BBB, blood–brain barrier; CNS, central nervous system; CNV, copy number 
variant; DAVID, Database for Annotation, Visualization, and Integrated Discovery; HDL, high-density lipoprotein; MeCP2, 
methyl CpG-binding protein; miRNA, microRNA; PPI, protein–protein interaction; SFARI, Simons Foundation Autism 
Research Initiative; SNP, single nucleotide polymorphism.
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cognition seen in a number of neuropsychiatric disorders (7). 
Here, we focus on miRNAs identified in studies of humans 
with autism spectrum disorder  (ASD).
Brain miRNA expression was first examined in postmortem 
cerebellum from ASD subjects (8). A succession of ensuing 
studies reported widespread miRNA dysregulation in the CNS 
and periphery, including lymphoblasts (9–11), blood (12–14), 
saliva (15), and olfactory precursor cells (16). These studies have 
produced vast amounts of information, some unifying and some 
conflicting. The way in which reports of circulating miRNAs 
instruct our understanding of miRNAs in the CNS is still being 
explored (17). To guide that exploration, this review summarizes 
current knowledge of miRNA in ASD, with the goal of identify-
ing the most consistent findings across studies with potential 
implications for biomarker discovery.
clinical Aspects of Autism spectrum 
Disorder
Autism spectrum disorder is a heterogeneous disorder typified 
by deficits in social communication and restricted, repetitive 
patterns of behavior (18). Children with ASD are often adher-
ent to daily routines, preoccupied with specific topics, and over 
sensitive to sensory inputs such as sounds or textures (19). In 
most cases, ASD symptoms are first recognized in early child-
hood. The average age of ASD diagnosis is 4 years (20). Rates of 
ASD are increasing. Recent reports from the Centers for Disease 
Control and Prevention estimate the prevalence of ASD to be 
1:68 children (1:45 among males) (21). This increase may be the 
result of multiple factors including public awareness, changes 
in diagnostic criteria, and environmental influences. However, 
genetics also plays an important role in ASD (22).
Genetic contributions to AsD
A large number of familial studies demonstrate that ASD is a 
heritable disorder (23, 24), with estimated genetic contribu-
tions accounting for >50–60% of ASD risk (25). Indeed, a large 
number of genetic variants and chromosomal abnormalities are 
linked to ASD (26). These variants tend to be highly penetrant 
but rare. However, in some cases, common variants with low 
penetrance have been reported (27). Neither explains the inci-
dence of ASD in the general population. Genetic epidemiologic 
studies have also shown that ASD is not a single disease but a 
constellation of symptoms involving multiple gene networks 
(28). Posttranscriptional mechanisms, such as miRNA, that 
broadly influence gene expression without altering the DNA 
code represent one means of altering entire gene networks (29). 
Increasingly, investigators have turned toward these mechanisms 
to explain the dysregulation of neurodevelopmental pathways 
that occurs in ASD (30, 31).
mirNAs regulate Posttranscriptional 
Gene expression
MicroRNAs are short (18–25 nucleotide), non-coding RNA mol-
ecules (32) that influence gene expression and numerous cellular 
processes, including proliferation, differentiation, and apoptosis 
(33). Over 2500 mature miRNAs (and 1800 precursors) have 
been identified in humans (34). Many of these are evolutionarily 
conserved (35). The genes for miRNAs are found in inter- or 
intra-genic regions (36). They are transcribed into precursor 
hairpin structures (pri-miRNAs) by RNA polymerase-II and 
trimmed into pre-miRNA by the RNase Drosha. After leaving 
the nucleus, Dicer liberates the pre-miRNA into a single-stranded 
molecule that can be bound within the miRNA-induced silencing 
complex (miRISC) (37). The targeting of the mature miRISC to 
individual mRNAs is based on the “seed sequences” that reside at 
the 5′ end of the miRNA and are complementary to the 3′ regions 
of mRNAs. Each seed sequence aligns with hundreds of mRNAs, 
and there are several miRNAs with shared seed sequences (38). 
Once bound to a target mRNA, the miRISC complex reduces the 
efficiency of gene expression by repressing protein translation or 
promoting degradation of the mRNA transcript (37).
mirNAs in the Brain and Periphery
MicroRNAs regulate approximately two-thirds of human 
mRNAs (39). Each miRNA has hundreds of potential mRNA 
targets, giving it the ability to modulate entire gene networks. In 
addition, miRNAs can circulate within exosomes, microvesicles, 
or RNA-binding proteins such as high-density lipoproteins, and 
thereby travel extracellularly to alter gene expression in distant 
tissues. This renders them exceedingly stable and easily measured 
in serum, plasma, saliva, urine, and other biofluids (40). However, 
miRNAs are most ubiquitous in the CNS, which expresses an 
estimated 70% of all miRNAs (41). Notably, expression of brain 
miRNAs changes throughout childhood and varies across brain 
regions (42). Neurons and glia are abundant sources of miRNAs, 
which can be readily transported across the blood–brain barrier 
(BBB). Moreover, miRNAs in neurons also help compartmental-
ize or localize mRNA expression and translation within specific 
subcellular regions such as axons and dendrites.
the role of mirNAs in Neurodevelopment
MicroRNAs play important roles in neurogenesis, synaptogen-
esis, and neuronal migration (43,  44). A major means by which 
these roles are manifest is the effect that neuronal miRNAs have 
on spatial localization or compartmentalization of protein trans-
lation in different neuronal subregions, such as axons, dendrites, 
and synapses (45, 46). Recent data support the relevance of these 
processes for neurodevelopmental disorders. For example, in 
mice with fragile X-associated tremor/ataxia syndrome (FXTAS), 
the fragile X mental retardation (FMR1) transcript is targeted by 
miR-221, miR-101, and miR-129-5p (47). Synaptosomal prepara-
tions from FXTAS mice demonstrate dysregulation of transcripts 
in learning and social interaction along with reduced levels of 
miR-221. Other examples include studies of disruption of miRNA 
regulatory genes such as Dicer or DGCR8, which produce altera-
tions in synaptic plasticity within the prefrontal cortex (48). The 
gene for DGCR8 is located at 22q11.21 and a well-characterized 
hemi-deletion of this region (referred to as velocardiofacial 
syndrome) produces a complex phenotype along with ASD traits 
in approximately one-third of subjects (49). Moreover, mice with 
DGCR8 haploinsufficiency have reduced dendrite complex-
ity, fewer neuronal spines, and decreased neurogenesis (50). 
Complementing these data, dysregulation of miRNA expression 
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has been described in a number of developmental, neuropsychi-
atric, and neurodegenerative disorders including schizophrenia, 
Alzheimer’s disease, and Parkinson’s disease (36).
the role of mirNAs in AsD Pathogenesis
Four studies examining postmortem brain tissue of human 
subjects with ASD have identified 91 miRNAs with differential 
expression compared with typically developing controls. The 
exact pathophysiologic role of these miRNAs in ASD remains 
unclear; however, many are implicated in neurogenesis and syn-
aptogenesis. A study of cerebellar cortex in 13 adults with ASD (8) 
identified 28 miRNAs with differential expression and 7 of these 
targeted the SHANK3 transcript. SHANK3 is involved in regula-
tion of synaptic density and has copy number variants (CNVs) 
and point mutations in nearly 1% of ASD cases (51). A study by 
Wu et al. (52) examined cerebellar cortex in 28 ASD subjects. The 
authors found miR-21-3p was upregulated in ASD subjects and 
demonstrated that its overexpression in human neuroprogenitor 
cells could repress multiple M16 hub genes, including DLGAP1 
(a scaffold protein that interacts with SHANK3). Thus, SHANK3 
represents one pathophysiologic target with an established role in 
ASD that appears to be targeted by multiple miRNAs identified in 
multiple studies of ASD brain tissue.
Overlapping mirNAs in AsD
This review synthesizes the findings of 12 studies, which compared 
miRNA expression in human cases of ASD to miRNA profiles in 
healthy controls (Table 1). Four of these studies involved brain 
tissue (8, 52–54), three involved peripheral blood (12–14), one 
examined saliva (15), one examined olfactory precursor cells 
(16), and three employed cultured lymphoblasts (9–11).
The 12 studies together identified 219 miRNAs with potential 
implications in ASD (Table  2A), including 185 unique and 34 
overlapping miRNAs (15.5%). Twenty-seven overlapping miR-
NAs changed in the same direction (Table  2B) in ≥2 studies, 
and 3 changed in the same direction in ≥3 studies (miR-23a, 
miR-146a, and miR-106b). Notably, 14 of the 27 miRNAs shared 
seed sequences with other ASD-associated miRNAs, suggesting 
that the pathophysiology of miRNA dysregulation in ASD might 
be controlled, at least in part, at the seed level. There is no single 
miRNA identified in all the 12 studies. This may be a function of 
ASD heterogeneity, miRNA tissue specificity, or advances in RNA 
quantification, which have led to varying alignment techniques 
and identification of new miRNAs.
Functional significance of Overlapping 
mirNAs and their Gene targets in AsD
Of the 27 overlapping miRNAs, 22 show differential regulation 
in studies of the CNS. The remaining five are expressed in the 
developing brain (42, 53). These 27 were predicted to target 1245 
mRNAs (Table S1 in Supplementary Material) with target scores 
≥93 (55).1 Notably, 86 of these mRNAs overlapped with the 519 
human ASD candidate genes with supportive evidence existing 
in the Simons Foundation Autism Research Initiative (SFARI) 
1 http://mirdb.org. 
database,2 representing a 6.6-fold enrichment for ASD-associated 
genes compared to chance (odds ratio: 7.7, 95th CI =  6.0–9.9, 
z = 16.2, p < 0.0001).
We next examined the evidence for functional enrichment of 
specific biologic processes using the Database for Annotation, 
Visualization, and Integrated Discovery (DAVID). This revealed 
225 total cluster mappings (56), with the top nodes including 
a KEGG pathway involved in neurotrophin signaling [n =  25 
genes, false discovery rate (FDR) =  0.0018]. In fact, this node 
had the largest fold change (FC) (3.0-fold) among all detected 
clusters (Table S2 in Supplementary Material). DAVID enrich-
ment analysis also identified 662 (55.9%) of the target mRNAs 
as expressed in brain tissue, with additional enrichment of genes 
expressed in epithelium (n = 268), fetal kidney (n = 35), placenta 
(n = 275), amygdala (n = 61), and T-cells (n = 37) (Table S3 in 
Supplementary Material).
To further examine functional relevance of the most probable 
mRNA targets, the Ingenuity Pathway Analysis (IPA) databases 
for “Canonical Pathways” and “Diseases and Biological Function” 
were used. These analyses were performed using a restricted 
set of 293 mRNAs that were predicted to be targets of the 27 
overlapping miRNAs with miRDB target scores ≥95. The results 
indicated enrichment of 20 Canonical Pathways (FDR < 0.05), 
including two related to neurotrophin signaling (Table S4 in 
Supplementary Material). Moreover, the “Diseases and Biological 
Function” analysis yielded a list of 500 networks for the 293 
mRNA targets, including 93 (18.6%) involved in brain function, 
of which 35 survived FDR correction (Table S5 in Supplementary 
Material). These represented several functions, including brain 
development, neurogenesis, neural and glial differentiation, 
synaptic development and function, and cognitive and motor 
function. The diseases identified among the brain-related 
networks included schizophrenia, abnormal brain morphology 
and trigeminal nerve morphology, abnormal posture, cognitive 
impairment, and seizure disorders.
Upstream Regulatory analysis was performed in IPA consider-
ing only experimentally observed and high-confidence miRNA–
mRNA interactions, which reduced our list of 27 miRNAs to 
20. Notably, 199 mRNAs were targeted by ≥2 miRNAs, and 55 
genes were targeted by ≥5 of the 20 miRNAs. The significance of 
this was determined using a Fisher’s exact test, which confirmed 
enrichment for 49 mRNAs (Table S6 in Supplementary Material). 
Protein–protein interaction (PPI) networks were also explored 
in the 199 target genes using the STRINGv10 database,3 which 
yielded a significant PPI network containing 137 edges and several 
nodes involved in brain function (Figure S1 in Supplementary 
Material). Among this network was an intriguing interaction 
between neuronal cell adhesion molecule (NRCAM; involved 
in directional signaling of axonal cone growth and implicated in 
ASD) (57), semaphorin 3a (SEMA3A; a chemoattractive agent 
involved in axon guidance) (58), and brain-derived neurotrophic 
factor (BDNF; essential for synaptogenesis in the developing 
hippocampus and altered in the periphery of ASD subjects) (59).
2 https://gene.sfari.org/autdb/HG_Home.do.
3 http://string-db.org/. 
tABle 1 | mirNA biomarker study characteristics and findings.
Abu-elNeel  
et al. (8)
Mor  
et al. (53)
Ander  
et al. (54)
Wu  
et al. (52)
vasu  
et al. (13)
Huang  
et al. (14)
Popov  
et al. (12)
Hicks  
et al. (15)
Nguyen  
et al. (16)
sarachana  
et al. (10)
talebizadeh  
et al. (9)
seno  
et al. (11)
Biomaterial Postmortem 
cerebellar 
cortex
Postmortem 
Brodmann’s 
area 10
Postmortem 
Brodmann’s 
areas 22, 41, 
and 42
Postmortem 
cerebellar 
cortex, 
Brodmann’s 
area 9
Serum Peripheral 
blood
Whole 
blood
Saliva Olfactory 
mucosal stem 
cells + skin 
fibroblasts or 
PBMCs
Lymphoblast 
cell lines
Lymphoblast cell 
lines
Lymphoblast 
cell lines
# participants 13 ASD, 13 
control
12 ASD, 12 
control
10 ASD, 8 
control
28 ASD, 28 
control
55 ASD, 55 
control
5 ASD/5 control 
(microarray), 
15ASD/15 
control 
(qRT-PCR)
30 ASD,  
25 control
24 ASD,  
21 control
8 ASD, 6 
control
14 ASD, 
14 sibling 
controls (3 
monozygotic 
twins)
6 ASD, 6 controls 20 ASD, 22 
sibling controls
ASD 
characteristics
Not described Age 30 
years, 83% 
male, ADI-R 
(no scores 
provided),  
PMI 26 h
Age 31 years, 
50% male, 
some ADI-R, 
Autism Tissue 
Program,  
PMI 23 h
Age 31 years, 
82% male, 
some ADI-R, 
17% with 15q 
duplication, 
PMI 24 h
Age 11 years, 
87% male, 
ADI-R (35), 
Japanese
Age 5 years, 
80% male, 
DSM-4 criteria, 
Chinese
Age 8 years, 
80% male, 
DSM-4 
criteria, 
Bulgarian
Age 9 years, 
79% male, 
ADOS (10.6), 
Vineland 
Adaptive 
Behavior (71)
Age 30 years, 
70% male, 
French
No ages, 
100% male, 
Autism 
Genetics 
Resource 
Exchange
Age 10 years 
old, 50% male, 
ADI-R (no scores), 
Autism Genetics 
Resource 
Exchange
No age or 
sex, ADOS 
(“severe,” but 
no scores), 
European
Measurement 
technique
qRT-PCR RNA-Seq 
with qRT-PCR 
validation
miRNA 
microarray, no 
validation
RNA-seq, 
qRT-PCR 
validation
PCR array 
with qRT-PCR 
validation
miRNA 
microarray 
with qRT-PCR 
validation
Microarray RNA-seq Microarray 
with qRT-PCR 
validation
miRNA 
microarray 
with qRT-PCR 
validation
miRNA microarray 
with qRT-PCR 
validation
miRNA 
microarray 
with qRT-PCR 
validation
# miRNAs  
tested
377 1104 1733 699 125 2578 Unknown 246 667 1237 150 708
# differentially 
expressed
28 20 6 58 14 44 1 14 4 43 9 16
% differentially 
expressed
7 2 0.3 8 11 2 Unknown 6 0.6 3 6 2
Criteria for 
differential 
expression
z-test of 
individual ASD 
Ct vs. pooled 
controls w/FDR
Two-tailed 
t-test with  
FDR < 0.05
p < 0.005, FC 
> 1.2
Linear mixed 
effects model, 
FDR < 0.05
Mann–Whitney 
pooled 
samples  
p < 0.05
Mann–Whitney  
p < 0.05
Welch’s  
p < 0.05, 
signal 
intensity >3
Mann–Whitney 
with  
FDR < 0.15
Mann–
Whitney p < 
0.05
Pavlidis 
Template 
Matching 
(PTM) analysis
p < 0.05 after 
Bonferroni, FC 
1.5
1.5 FC in 
≥12/24 
sibling-pair 
comparisons
# overlapping 
with other 
studies
29 35 0 14 14 16 0 43 1 25 44 13
Largest  
change
miR-484 
(downregulated 
in 3 ASD 
participants)
miR-338-5p 
(4.4 FC,  
p = 5.47E−81)
miR-297 
(−1.24 FC,  
p = 0.0012)
miR-3687 
(−1.5 FC, 
FDR 1.5E−4)
miR-572 miR-451a  
(p = 4.58E−5)
miR-486-3p 
(p = 0.03)
miR-628-5p (Z 
diff 1.13, FDR 
0.027)
miR-146a  
(p < 0.001)
miR-182-AS 
(−1.54 FC, 
1.44E−03)
miR-132 
(changed in all 6 
ASD individuals)
miR-199b-5p 
(1.81 FC,  
p = 2.51E−05)
ADI-R, Autism Diagnostic Inventory – Revised; ADOS, Autism Diagnostic Observation Schedule; ASD, autism spectrum disorder; Ct, cycles-to-threshold; FC, fold change; FDR, false discovery rate correction; PMI, postmortem 
interval; qRT-PCR, quantitative reverse-transcription/real time polymerase chain reaction; RNA-Seq, ribonucleic acid sequencing; sib, sibling.
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tABle 2 | cross-tissue mirNA biomarkers with seed sequences.
A. Brain serum saliva lymphoblast Olfactory scs
Abu-elNeel 
et al. (8)
Mor  
et al. (53)
Ander  
et al. (54)
Wu  
et al. (52)
vasu  
et al. (13)
Huang  
et al. (14)
Popov  
et al. (12)
Hicks et al. 
(15)
sarachana 
et al. (10)
talebizadeh 
et al. (9)
seno  
et al. (11)
Nguyen  
et al. (16)
Up-regulated miR-106a mir-7-5p miR-664-3p mir-10a-5p mir-19b-3p miR-34b-3p mir-7-5p miR-16-2 miR-23a mir-10a mir-146a
mir-106b miR-19a-3p miR-4709-3p miR-18b-5p miR-27a-3p miR-34c-3p miR-28-5p mir-106b miR-23b miR-30a
mir-140 mir-19b-3p miR-4753-5p miR-20b-5p miR-101-3p miR-483-5p miR-127-3p mir-132 mir-132 miR-181a
mir-146b mir-21-3p mir-21-3p mir-106-5p mir-494 mir-140-3p miR-133b mir-146a miR-181b
miR-181d miR-21-5p mir-23a-3p miR-130a-3p miR-564 miR-191-5p miR-136 mir-146b miR-181c
miR-193b miR-142-3p miR-107 miR-195b-5p miR-574-5p miR-218-5p miR-139 miR-663 mir-199b-5p
miR-320a miR-142-5p miR-129-2-3p miR-575 mir-335-3p miR-148b miR-338-3p
miR-381 miR-144-3p miR-130b-5p miR-921 miR-628-5p miR-153 miR-486-3p
miR-432 mir-146a-5p miR-148a-3p miR-1246 miR-2467-5p miR-182 miR-486-5p
miR-539 mir-155-5p mir-155-5p miR-1249 miR-3529-3p miR-189 miR-500
miR-550 mir-219-5p miR-218-2-3p miR-1273c miR-190 miR-502-3p
miR-652 mir-338-5p miR-221-3p miR-4270 mir-199b miR-548
miR-379-5p miR-223-3p miR-4299 miR-211
miR-451a mir-335-3p miR-4436a mir-219
mir-494 miR-363-3p miR-4443 miR-326
miR-3168 miR-424-3p miR-4516 miR-367
miR-424-5p miR-4669 miR-455
miR-425-3p miR-4721 miR-495
miR-449b-5p miR-4728-5p miR-518a
miR-450b-5p miR-4788 miR-520b
miR-484 miR-5739
miR-629-5p miR-6086
miR-651-5p miR-6125
miR-708-5p miR-642a-3p
miR-766-3p
miR-874-3p
miR-887-3p
miR-940
miR-1277-3p
miR-3938
miR-2277-5p
let-7g-3p
Down-regulated miR-7 miR-34a-5p miR-1 miR-204-3p miR-151a-3p mir-15a-5p miR-486-3p mir-23a-3p mir-23a mir-92 miR-199a-5p miR-221
mir-15a mir-92b-3p miR-297 miR-491-5p miR-181b-5p mir-15b-5p mir-27a-3p miR-23b mir-320 miR-455-3p miR-654-5p
mir-15b miR-211-5p miR-4742-3p miR-619-5p mir-320a miR-16-5p mir-30e-5p miR-25 miR-363 miR-577 miR-656
miR-21 miR-3960 miR-3687 miR-328 miR-19b-3p miR-32-5p miR-29b miR-650
mir-23a miR-5096 miR-433 miR-20a-5p mir-30e
mir-27a miR-489 mir-92a-3p mir-93
miR-93 miR-572 mir-103a-3p mir-103
miR-95 miR-663a mir-195-5p miR-107
miR-128 mir-451a miR-185
miR-129 miR-574-3p miR-186
miR-132 miR-940 miR-191
miR-148b miR-1228-3p miR-194
tABle 2 | continued
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miR-212 miR-3613-3p mir-195
miR-431 miR-3935 miR-205
miR-484 miR-4436b-5p miR-342
miR-598 miR-4665-5p miR-346
miR-4700-3p miR-376a-AS 
let-7a-5p mir-451
let-7d-5p miR-519c
let-7f-5p miR-524
Direction of change in different biomaterials
B. mirNA iD seed 
sequence
Human mirNAs with same seed cNs Blood saliva lymphoblast Olfactory
miR-7-5p GGAAGAC ↑↓ ↑
miR-10a-5p ACCCUGU miR-10a-5p miR-10b-5p ↑ ↑
miR-15a-5p AGCAGCA miR-15a-5p miR-15b-5p mir-16-5p mir-195-5p miR-424-5p miR-497-5p 
[miR-6838-5p]
↓ ↓
miR-15b-5p AGCAGCA miR-15a-5p miR-15b-5p mir-16-5p mir-195-5p miR-424-5p miR-497-5p 
[miR-6838-5p]
↓ ↓
miR-19b-3p GUGCAAA mir-19a-3p ↑ ↑↓
miR-21-3p AACACCA miR-3591-3p ↑↑
miR-23a-3p UCACAUU miR-23-3p mir-23b-3p miR-23c [miR-130a-5p] ↑↓ ↓ ↓↑
miR-27a-3p UCACAGU miR-27-3p miR-27b-3p ↓ ↑ ↓
miR-30e-5p GUAAACA miR-30a-5p miR-30b-5p miR-30c-5p miR-30d-5p miR-30-5p ↓ ↓↑
miR-92a-3p AUUGCAC mir-25-3p mir-32-5p miR-92-3p miR-92b-3p mir-363-3p miR-367-3p ↓ ↓
miR-92b-3p AUUGCAC mir-25-3p mir-32-5p miR-92-3p miR-92b-3p mir-363-3p miR-367-3p ↓ ↓
miR-93 AAAGUGC miR-17-5p mir-20a-5p miR-20b-5p miR-93-5p miR-106a-5p miR-106b-5p 
miR-519d-3p miR-526b-3p
↓ ↓
miR-103a-3p GCAGCAU miR-103-3p ↓ ↓
miR-106b-5p AAAGUGC miR-17-5p miR-20a-5p miR-20b-5p miR-93-5p mir-106a-5p miR-519d-3p 
[miR-526b-3p]
↑ ↑ ↑
miR-132 AACAGUC miR-132-3p miR-212-3p ↑↑
CCGUGGC miR-132-5p
miR-140-3p ACCACAG ↑ ↑
miR-146a-5p GAGAACU miR-146a-5p mir-146b-5p [miR-7153-5p] ↑ ↑ ↑
miR-146b GAGAACU mir-146a-5p mir-146b-5p [miR-7153-5p] ↑ ↑
miR-155-5p UAAUGCU ↑↑
miR-195-5p AGCAGCA mir-15a-5p mir-15b-5p mir-16-5p miR-424-5p miR-497-5p [miR-6838-5p] ↓↑ ↓
miR-199b-5p CCAGUGU miR-199a-5p ↑↑
miR-219-5p GAUUGUC miR-219a-5p [miR-4782-3p] [miR-6766-3p] ↑ ↑
miR-320a AAAGCUG miR-320b miR-320c miR-320d [miR-4429] ↑ ↓ ↓
miR-335-3p UUUUCAU ↑ ↑
miR-338-5p ACAAUAU ↑ ↑
miR-451a AACCGUU ↑ ↓ ↓
miR-494 GAAACAU miR-494-3p ↑ ↑
GGUUGUC miR-494-5p miR-323b-5p miR-410-5p
% overlap 23.1 19.0 42.8 25.8 25.0
Boldface miRNAs change in the same direction in multiple tissues. Italic miRNAs change in different directions in multiple studies. Lower left indicates miRNAs that share the same seed sequence as those that appear changed in 
multiple studies. Lower right indicates predominant direction of change in ASD subjects relative to controls for each biomaterial. For tissues with opposing changes both arrows are shown.
CNS, central nervous system; SCs, stem cells.
The final row shows the proportion of altered miRNAs for each biomaterial that overlap with other studies.
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expression of mirNA across Brain 
regions
MicroRNA expression is a dynamic process, changing through-
out development and across brain regions (43). A study of 
non-coding RNA in the superior temporal gyrus of ASD subjects 
demonstrated changes in regional miRNA profiles that could 
contribute to ASD (60). Specifically, while miRNA patterns in the 
superior temporal sulcus (a region relevant to social interaction) 
and primary auditory cortex changed throughout development 
in the typical brain, many of the changes were blunted in subjects 
with ASD. Four of the individual miRNAs identified (miR-93-3p, 
miR-103, miR-132, and miR-320) were among the 219 miRNAs 
altered in other studies of ASD, with 3 of the 4 changed in multiple 
studies (Table 2).
Potential Mechanisms for mirNA 
Dysregulation
The molecular mechanisms underlying miRNA dysregulation 
in ASD are still being explored. One explanation is that autistic 
miRNA patterns may represent a permanent response to an early 
environmental insult, such as perinatal hypoxia (61). In this sce-
nario, miRNA regulation could be disrupted by a layer of epigenetic 
machinery such as DNA methylation. In a study of 12 subjects 
with ASD, expression of miR-142 was increased in Brodmann’s 
area 10 compared with healthy controls – a change accompanied 
by hypomethylation of the miR-142 promoter region (53).
Another possible mechanism is that individual miRNAs 
sequences are altered in children with ASD. Pooled analysis of 
common and rare single nucleotide polymorphisms (SNPs) in 
449 cases of ASD using whole exome sequencing has identified 2 
miRNA clusters: miR-133b/miR-206 and mir-17/miR/18a/miR-
19a/miR20a/miR-19b-1/miR-92a (62). Four of these individual 
components have disrupted expression levels in children with 
ASD, and miR-92a is downregulated in multiple studies (9, 14).
Yet another explanation could be that the location of specific 
miRNAs at CNV loci leads to their dysregulation. Of the 41 CNV 
loci associated with ASD, >10% contain miRNAs (63). Three of 
the 10 “hub miRNAs” (i.e., miRNAs at CNV loci with the great-
est gene network connectivity) have been previously identified 
in studies of ASD (miR-34a, miR-548, and miR-195) and target 
multiple genes involved in neurodevelopment. Alterations in 
miR-195 have been reported in serum (13, 14) and lymphoblasts 
(10) of ASD individuals. Furthermore, a key gene involved in 
miRNA synthesis (Dicer) was identified as a common target 
for many of the hub miRNAs, suggesting that some CNVs in 
ASD might cause extensive dysregulation of the entire miRNA 
machinery.
systemic mirNA Dysregulation
Although the brain is considered the primary pathological target 
in ASD, alterations in miRNA expression have been noted in a 
number of other body sites (13, 15). This may explain (in part) 
why children with ASD experience medical comorbidities out-
side the CNS, including gastrointestinal issues such as esophageal 
reflux and constipation (64). They also have altered oral-motor 
function (speech apraxia) and sensory processing (65, 66). Given 
these comorbidities, it should come as no surprise that oral 
miRNA patterns are altered in children with ASD. In addition, 
the proximity of the oropharynx to the CNS and its abundant 
sensory and motor nerve innervation (involving branches of the 
glossopharyngeal, facial, vagus, and trigeminal nerves) could 
provide an ample source of miRNA (67, 68).
Alterations in miRNA profiles of peripheral blood sites may be 
explained by circulating miRNA that has crossed the BBB (espe-
cially considering that ASD is not associated with hematologic 
disorders). In peripheral sources such as blood, brain-related 
miRNA may be stable and abundant as a result of exosomal trans-
port (13, 14). Thus, while biofluids such as serum and saliva may 
not represent optimal models for studying CNS pathophysiology, 
they may represent ideal reservoirs for ASD biomarkers.
employing mirNAs as Biomarkers
The potential of miRNAs as biomarkers in ASD has been explored 
in studies of serum and saliva. In a study of serum miRNAs from 
55 children with ASD, the authors identified three miRNAs (miR-
130-3p, miR-181b-5p, and miR-320a) with an area under the 
curve (AUC) >0.85 (13). In our own more recent study, involving 
24 children with ASD, a set of 14 salivary miRNAs showed more 
than 95% accuracy (AUC = 0.92) at differentiating control and 
ASD subjects (15). This study also showed that expression pat-
terns of individual salivary miRNAs were significantly correlated 
with several measures of adaptive behavior. This highlights how 
the utility of miRNA extends beyond simple ASD diagnosis and 
may 1 day be used to predict ASD phenotype and severity.
cONclUsiON
It is clear that miRNA profiles are dysregulated across multiple 
tissue types in subjects with ASD. This review encapsulated 219 
target miRNAs from 12 human studies of ASD and identified 27 
that were dysregulated in ≥2 investigations. Functional pathway 
analysis supports the idea that these miRNAs target brain-
expressed genes related to neurodevelopment and implicated 
in ASD. Three miRNAs showed consistent dysregulation across 
≥3 studies (miR-23a-3p, miR-146a-5p, and miR-106b-5p). The 
networks of genes targeted by these miRNAs are implicated in 
ASD and have significant roles in neurotrophin signaling. BDNF, 
which is important for hippocampal neurogenesis and decreased 
in the serum of adult ASD patients (59), is targeted by 6 of the 
27 miRNAs of interest. Animal and cell models that assess these 
molecular mechanisms behind miRNAs and their mRNA targets 
will be critical in advancing the current ASD knowledge-base.
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FiGUre s1 | Protein–protein interaction (PPi) network of the genes that 
are targeted by 2 or more of at least 20 of the 27 conserved mirNAs 
affected across studies. This analysis involved mapping of 199 mRNA targets 
in the STRING v10 database (http://string-db.org/). Note the presence of a 
significant interaction network containing 137 edges for the 197 targets with 
annotation information available. Notably, only genes with connections are 
included in the PPI. Also, note that many of these genes were involved in 
brain-related functions, including some that mapped to a neuronal projection 
Gene Ontology (highlighted in red).
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